MARKET

PRNAF

PRNAF

Alterity Therapeutics Ltd
OTCPK
0.139
-0.061
-30.40%
Closed 13:49 11/20 EST
OPEN
0.139
PREV CLOSE
0.200
HIGH
0.139
LOW
0.139
VOLUME
5.00K
TURNOVER
696
52 WEEK HIGH
0.540
52 WEEK LOW
0.010
MARKET CAP
31.90M
P/E (TTM)
-1.8101
1D
5D
1M
3M
1Y
5Y
1D
Alterity Therapeutics Reports 2026 Annual General Meeting Results
TipRanks · 2d ago
Alterity Reports FDA Alignment on ATH434 Phase 3 Design
TipRanks · 2d ago
Alterity Therapeutics Secures FDA Alignment and New Patent as ATH434 Advances Toward Phase 3
TipRanks · 10/30 01:13
Alterity Therapeutics Plans New ASX Option Issue to Bolster Capital Structure
TipRanks · 10/23 05:39
Alterity Therapeutics Issues New Unlisted Employee Options
TipRanks · 10/22 23:48
Alterity Therapeutics Grants New Unlisted Employee Options
TipRanks · 10/22 23:48
Alterity Therapeutics Sets Hybrid 2026 AGM, Urges Early Proxy Voting
TipRanks · 10/21 05:18
Alterity Therapeutics Updates CEO Remuneration as Neurodegeneration Programs Advance
TipRanks · 10/21 05:17
More
About PRNAF
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.

Webull offers Alterity Therapeutics Ltd stock information, including OTCPK: PRNAF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRNAF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRNAF stock methods without spending real money on the virtual paper trading platform.